Article Versions Notes

Luque-Navarro PM, Mariotto E, Ballarotto M, Rubbini G, Aguilar-Troyano FJ, Fasiolo A, Torretta A, Parisini E, Macchiarulo A, Laso A, et al. Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors. Pharmaceutics. 2022; 14(4):715. https://doi.org/10.3390/pharmaceutics14040715

Luque-Navarro, Pilar María, Elena Mariotto, Marco Ballarotto, Gianluca Rubbini, Francisco José Aguilar-Troyano, Alberto Fasiolo, Archimede Torretta, Emilio Parisini, Antonio Macchiarulo, Alejandro Laso, and et al. 2022. "Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors" Pharmaceutics 14, no. 4: 715. https://doi.org/10.3390/pharmaceutics14040715

Luque-Navarro, P. M., Mariotto, E., Ballarotto, M., Rubbini, G., Aguilar-Troyano, F. J., Fasiolo, A., Torretta, A., Parisini, E., Macchiarulo, A., Laso, A., Marco, C., Viola, G., Carrasco-Jimenez, M. P., & López-Cara, L. C. (2022). Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors. Pharmaceutics, 14(4), 715. https://doi.org/10.3390/pharmaceutics14040715